Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COLLABORATION FRAMEWORK AGREEMENT WITH SAFE PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.*

This is a voluntary announcement made by Genscript Biotech Corporation (the "**Company**" together with its subsidiaries, the "**Group**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 22 October 2018 (after trading hours), (i) Nanjing Jinsirui Biotechnology Co., Ltd.* 南京金斯瑞生物科技有限公司, an indirect wholly-owned subsidiary of the Company ("**Nanjing Jinsirui**"), and (ii) SAFE Pharmaceutical Research Institute Co., Ltd.* 北京賽賦醫藥研究院有限公司, a contract research organization ("**CRO**") company that provides pharmacology, pharmacokinetics, formulation, toxicology and safety evaluation services ("**SAFE PHARM**"), entered into a strategic collaboration framework agreement (the "**Agreement**") in relation to the parties' collaboration (the "**Collaboration**") based on Nanjing Jinsirui's integrated biologics discovery and development platform and SAFE PHARM's pharmacology, toxicology and safety evaluation services.

THE COLLABORATION

The parties' Collaboration shall be based on Nanjing Jinsirui's integrated biologics discovery and development technology and SAFE PHARM's pharmacology, toxicology and safety evaluation service system to jointly build a high-quality, high-standard one-stop biologics discovery and development platform that provides services from target discovery to IND (investigational new drug).

REASONS FOR THE COLLABORATION

Preclinical discovery and development of biologics generally requires up to 1.5 to 2 years to complete with the involvement of various contracted suppliers. The Company believes that the Collaboration shall improve the integration of preclinical projects, enable the seamless connection among CMC (chemistry manufacturing and control), pharmacology, toxicology and reagent development, and can shorten the project cycle by up to 6 months, thereby accelerating the progress in the development of biologics projects. In addition, through the Collaboration, the parties intend to jointly establish an expert team comprising senior scientists in new drug discovery and development and drug evaluation experts with years of experience with the aim to offer professional guidance on, including but not limited to target selection, new drug discovery and development and IND filing of biologics projects, follow up domestic and international policies, and adjust development programs in a timely fashion, thereby ensuring the successful implementation of projects.

The Company believes that the Collaboration between Nanjing Jinsirui and SAFE PHARM shall, by combining and complementing each other's strengths, strive to develop a high-quality, high-standard one-stop biologics discovery and development platform, and drive biologics discovery and development by virtue of innovative biologics discovery and development technologies and high-quality services.

INFORMATION ON THE GROUP AND NANJING JINSIRUI

The Company has been focusing on the discovery and development of biologics for over 15 years, and is devoted to accelerating the discovery and development of biologics through the application of innovative biologics research technologies, highly integrated biologics discovery, development and production platform. As a leading innovative biologics contract development and manufacturing organization ("**CDMO**"), the Company provides new discovery and development ideas and tools for global innovative biologics discovery and development with innovative technology platforms such as SMAB (single domain antibody fused to monoclonal antibody) bispecific antibody and fully human naïve library（全人文庫）. As an integrated CDMO, the Company provides biologics discovery, development and IND filing services covering the entire life cycle of biologics discovery and development, and will extend its services into the clinical sample production and commercial production process in the future.

Nanjing Jinsirui is a limited liability company incorporated in the People's Republic of China and is an indirect wholly-owned subsidiary of the Company.

INFORMATION ON SAFE PHARM

SAFE PHARM is a limited liability company established under the laws of the People's Republic of China. It provides pharmacology, pharmacokinetics, formulation, toxicology and safety evaluation services. To the best knowledge and belief of the Company, SAFE PHARM and its ultimate beneficial owners are third parties independent of the Company.

The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 23 October 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*